Finally, at the time of writing, there are several other AOMs under study for the treatment of obesity in both the adult and adolescent populations including tirzepatide, a GLP1/ glucose-dependent insulinotropic polypeptide (GIP) co-agonist which is approved in adult patients and currently undergoing trials in adolescents as well as novel amylin agonists and peptide YY agonists [49]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.